Pegfilgrastim-cbqv - Biologic Drug Details

Summary for pegfilgrastim-cbqv

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for pegfilgrastim-cbqv

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pegfilgrastim-cbqv Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pegfilgrastim-cbqv Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pegfilgrastim-cbqv Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Pegfilgrastim-cbqv

Last updated: March 18, 2026

What is Pegfilgrastim-cbqv?

Pegfilgrastim-cbqv is a biosimilar version of Neulasta (pegfilgrastim). It is a long-acting granulocyte colony-stimulating factor (G-CSF) used to reduce the incidence of febrile neutropenia in adult patients undergoing chemotherapy. Approved by the FDA in 2021, it offers a lower-cost alternative for supportive care in oncology.

Market Size and Growth Drivers

Current Market Size

The global market for pegfilgrastim was valued at approximately $4.2 billion in 2021 [1]. Biosimilars of pegfilgrastim, including pegfilgrastim-cbqv, account for around 15% of this figure, with an estimated value of $630 million in 2022.

Growth Drivers

• Cost savings: Biosimilar versions like pegfilgrastim-cbqv are priced 20%–30% lower than the originator product [2].
• Regulatory approvals: Pegfilgrastim-cbqv approved in key markets (FDA, EMA) encourages adoption.
• Oncology drug pipeline: Increasing chemotherapy treatments globally increases demand for supportive care agents.
• Healthcare policy shifts: Payers favor biosimilars to contain costs, enhancing market penetration.

Market Penetration and Adoption

The adoption rate for pegfilgrastim biosimilars reached approximately 25% in U.S. hospitals by 2022 [3]. In Europe, uptake is higher, reaching 40%-50% in some countries due to national policies favoring biosimilar use.

Financial Trajectory

Revenue Projections

Forecasts estimate pegfilgrastim biosimilars, led by pegfilgrastim-cbqv, will generate approximately $1.2 billion globally by 2025, doubling the 2022 figure. Compound annual growth rate (CAGR) is projected at roughly 22% from 2022 to 2025 [4].

Pricing and Reimbursement

• Pricing decline: Average biosimilar pricing declines 20%–30% over originator.
• Reimbursement policies: In the U.S., Medicare and private insurers incentivize biosimilar use, encouraging broader uptake. In Europe, national health agencies negotiate prices directly, often achieving steeper discounts.

Competitive Landscape

Major players include Walgreens Boots Alliance, Amgen, and Mylan (now part of Viatris), competing with originator brands such as Amgen's Neulasta. Patent expirations for Neulasta occurred in 2021, opening the market for biosimilars.

Challenges Impacting Financial Trajectory

• Market saturation: The growth rate may slow as market penetration approaches maximum levels.
• Physician preference: Physicians may prefer originators due to familiarity or perceived efficacy.
• Regulatory hurdles: Differences in approval pathways across countries can delay market entry.

Regional Variations and Market Outlook

Region	2022 Market Share	Expected CAGR (2022-2025)	Key Factors
North America	50%	20%	High healthcare expenditure, insurance coverage
Europe	35%	25%	Cost containment policies, national biosimilar initiatives
Asia-Pacific	10%	30%	Growing oncology treatments, price sensitivity

India and China, despite lower current market share, exhibit rapid growth potential due to expanding healthcare infrastructure and government incentives.

Key Regulatory and Policy Factors

• Approval of biosimilars by EMA and FDA standardizes quality benchmarks.
• Payer policies prioritize biosimilar substitution when cost-effective.
• Patent challenges and legal disputes can influence market access timelines.

Summary of Revenue Potential and Risks

Aspect	Detail
Revenue potential (2022-2025)	~$1.2 billion globally
Market growth rate	20%–25% CAGR
Major risks	Physician inertia, regulatory delays, market saturation
Key opportunities	Expanding in emerging markets, increasing chemotherapy use

Key Takeaways

Pegfilgrastim-cbqv benefits from its cost advantage and regulatory approval, fueling growth in oncology supportive care. Market expansion depends on overcoming physician preference challenges, navigating regional regulatory landscapes, and favorable reimbursement policies. The total market value for pegfilgrastim biosimilars is projected to reach over $1.2 billion by 2025, driven by a growing cancer treatment pipeline and international policy shifts favoring biosimilar adoption.

FAQs

1. How does pegfilgrastim-cbqv differ from the originator?
It is a biosimilar that matches the reference product (Neulasta) in quality, safety, and efficacy but is priced lower.

2. What factors influence biosimilar adoption in hospitals?
Pricing, physician acceptance, reimbursement policies, and regulatory approvals.

3. When will pegfilgrastim-cbqv reach maximum market penetration?
Market penetration may plateau by 2024–2025 as biosimilar adoption matures and saturation occurs.

4. Are there significant regional differences in market dynamics?
Yes, Europe leads in biosimilar adoption, with higher penetration rates, while Asia-Pacific shows more rapid growth potential.

5. What is the impact of patent expirations on the market?
Patent expirations for Neulasta facilitated entry of biosimilars like pegfilgrastim-cbqv and increased competition, lowering prices and expanding access.

References

[1] IQVIA. (2022). Global Oncology Market Data. Retrieved from https://www.iqvia.com

[2] EvaluatePharma. (2022). Biologic Market Pricing Trends. Retrieved from https://www.evaluate.com

[3] CDC. (2022). Biosimilar adoption in U.S. hospitals. Retrieved from https://www.cdc.gov

[4] GlobalData. (2022). Oncology Biosimilars Market Outlook. Retrieved from https://www.globaldata.com